Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses BLIN-01 trial which looks at blinatumomab use during consolidation in adult patients with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia.
He outlines the trial design, results and toxicity profile.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.